Inhalable insulin prescribing information revised to include lung malignancy occurrence

Pfizer revises package insert after reports of lung cancer in patients receiving their inhaled insulin.

Pfizer has issued letters to both healthcare professionals and patients to inform them of six reported cases of newly diagnosed primary lung malignancy during clinical trials in patients using their insulin human [rDNA origin] inhalation powder (